The major pathways of DNA double-strand break (DSB) repair are crucial for maintaining
genomic stability. However, if deployed in an inappropriate cellular context, these same …

BRCA1 (BReast‐CAncer susceptibility gene 1) and BRCA2 are tumor suppressor genes, the
mutant phenotypes of which predispose to breast and ovarian cancers. Intensive research …

Defective DNA repair by homologous recombination (HR) is thought to be a major
contributor to tumorigenesis in individuals carrying Brca1 mutations. Here, we show that …

Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer
treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary …

The aim of this study is to estimate the frequency of pathologic complete response (pCR)
after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a …

The discovery of the first gene associated with hereditary breast cancer, BRCA1, was
anticipated to greatly increase our understanding of both hereditary and sporadic forms of …

BRCA1 and BRCA2 are often mutated in familial breast and ovarian cancer. Both tumor
suppressors play key roles in the DNA-damage response [1, 2]. However, it remains unclear …

The number of available breast cancer cell (BCC) lines is small, and only a very few of them
have been extensively studied. Whether they are representative of the tumours from which …

Fanconi anemia (FA) is a human autosomal recessive cancer susceptibility disorder
characterized by cellular sensitivity to mitomycin C and ionizing radiation. Although six FA …

We report the identities of the members of a group of proteins that associate with BRCA1 to
form a large complex that we have named BASC (B RCA1-a ssociated genome s urveillance …